The tumors on the mammary glands included several variants of the invasive ductal carcinogenic cells, whereas in the ovaries, the tumors found were granulosa cell tumors
Conservative combination protocol (if attempting) Rationale for conservative approach: No safety data available Both peptides slow gastric emptying significantly Risk of severe GI complications Start low, go slow principle Tirzepatide component: Follow standard FDA-approved titration Weeks 1-4: 2.5mg weekly Weeks 5-8: 5mg weekly Weeks 9-12: 7.5mg weekly Weeks 13-16: 10mg weekly Week 17+: 12.5mg weekly (or stay at 10mg) Some reach 15mg weekly (maximum) Cagrilintide component (reduced from standard): Start AFTER tirzepatide stabilized at therapeutic dose (week 13+) Week 13-16: 0.6mg weekly (lower than standard) Week 17-20: 1.2mg weekly Week 21-24: 1.8mg weekly (may be maximum tolerable) Consider 2.4mg only if tolerating perfectly Conservative dosing comparison: Why sequential is safer: Tirzepatide establishes baseline first Can attribute new side effects to cagrilintide Easier to manage one variable at a time Option to stop cagrilintide if intolerable Less overwhelming than both simultaneously Expected benefits: 18-25% total weight loss (conservative estimate) Potentially superior to tirzepatide alone (15-22%) But incremental benefit may be modest (3-5% additional) Use SeekPeptides to plan sequential peptide additions safely
Chicnutrix Glow OPITAC Glutathione | Score: 82/100 Best 500 mg effervescent choice with a named Japanese source
GHK-Cu (copper tripeptide-1) is a cosmetic ingredient and is not approved by the FDA, EMA, or any comparable regulator for the treatment, cure, or prevention of androgenetic alopecia, telogen effluvium, or any other hair-loss condition
At Hims & Hers (and other telehealth companies with their own compounding divisions), patients are sent drugs with a stamp of approval from a Hims & Hers-affiliated doctor who will order the prescription through the Hims & Hers compounding pharmacy
